TriGenix done in by a string of bad luck

Noteworthy

TriGenix done in by a string of bad luck

TriGenix Inc. is planning on closing its doors, a victim both of D. Blech's financial problems and the failure of Celtrix Pharmaceuticals Inc.'s Phase III BetaKine trial to show efficacy in macular holes.

TriGenix was launched in

Read the full 476 word article

How to gain access

Continue reading with a
two-week free trial.